Lücke Eva, Schraven Burkhart, Borucki Katrin, Lux Anke, Reinhold Dirk, Wu Qingyu, Schreiber Jens
Department of Pneumology, Otto-von-Guericke University, Magdeburg, Germany.
Institute of Molecular and Clinical Immunology, Otto-von-Guericke University, Magdeburg, Germany.
J Asthma. 2023 Nov;60(11):2021-2029. doi: 10.1080/02770903.2023.2213327. Epub 2023 May 31.
Severe asthma is heterogeneous, with childhood-onset asthma believed more likely to be allergic, whereas adult-onset asthma is considered typically non-allergic. However, the allergic diagnosis is typically by exclusion: if patients do not react to an allergen panel, which is not standardized and often limited to few allergens, they are considered non-allergic. The overall aim of the ATLAS study was to characterize the sensitization to allergens in severe asthma (independent of phenotype).
Single-visit, cross-sectional, non-interventional study in adults with severe asthma. Analyses were conducted for total and specific immunoglobulin E against 53 allergens, overall and in subgroups, including age at asthma onset (<20 [childhood-onset] and >40 years of age).
Among 1010 recruited patients, 28.4% reported childhood-onset asthma and 33.6% onset >40 years of age. After excluding patients receiving omalizumab/anti-IL5 therapy, 27.6% were not sensitized to any tested allergens, whereas 19.1% were sensitized to >10 allergens. All allergens triggered sensitization in some patients. Baseline characteristics in the two onset subgroups were similar; 23.2% with childhood-onset asthma were not sensitized to any allergen, compared to 32.0% with onset >40 years of age.
When a broad panel of allergens is used for sensitization testing, as many as three quarters of patients with severe asthma display sensitivity to at least one allergen, with substantial overlaps in all characteristics between the two age-at-onset subgroups. All of the tested allergens triggered a response in at least some patients, emphasizing the importance of including a broad range of allergens in any testing panel.
重度哮喘具有异质性,儿童期起病的哮喘被认为更可能是过敏性的,而成人期起病的哮喘通常被认为是非过敏性的。然而,过敏性诊断通常是通过排除法:如果患者对一组过敏原没有反应(该过敏原检测 panel 不标准化且通常限于少数几种过敏原),他们就被认为是非过敏性的。ATLAS 研究的总体目标是描述重度哮喘患者对过敏原的致敏情况(独立于表型)。
对成年重度哮喘患者进行单次就诊、横断面、非干预性研究。针对 53 种过敏原进行总免疫球蛋白 E 和特异性免疫球蛋白 E 的分析,整体及在亚组中进行分析,包括哮喘起病年龄(<20 岁[儿童期起病]和>40 岁)。
在 1010 名招募的患者中,28.4%报告为儿童期起病的哮喘,33.6%起病年龄>40 岁。排除接受奥马珠单抗/抗白细胞介素-5 治疗的患者后,27.6%对任何测试过敏原均未致敏,而 19.1%对>10 种过敏原致敏。所有过敏原在一些患者中均引发致敏。两个起病亚组的基线特征相似;23.2%的儿童期起病哮喘患者对任何过敏原均未致敏,而>40 岁起病的患者这一比例为 32.0%。
当使用广泛的过敏原 panel 进行致敏检测时,多达四分之三的重度哮喘患者对至少一种过敏原敏感,两个起病年龄亚组在所有特征上存在大量重叠。所有测试的过敏原在至少一些患者中均引发了反应,强调了在任何检测 panel 中纳入广泛过敏原的重要性。